Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension

Diederik E. van der Feen,Kondababu Kurakula,Eve Tremblay,Olivier Boucherat,Guido P.L. Bossers,Robert Szulcek,Alice Bourgeois,Marie-Claude Lampron,Karima Habbout,Sandra Martineau,Roxane Paulin,Ewelina Kulikowski,Ravi Jahagirdar,Ingrid Schalij,Harm-Jan Bogaard,Beatrijs Bartelds,Steeve Provencher,Rolf M.F. Berger,Sébastien Bonnet,Marie-José Goumans

Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension

2019

RATIONALE. Pulmonary arterial hypertension (PAH) is a degenerative arteriopathy that leads to right ventricular (RV) failure. Bromodomain-containing protein 4 (BRD4), a member of the Bromodomain an...

Keywords:

Anesthesia
Medicine
Diabetes mellitus
Cardiology
Internal medicine
Bromodomain
BRD4
Receptor
Inflammation
FOXM1
Cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations